<DOC>
	<DOCNO>NCT01145612</DOCNO>
	<brief_summary>The purpose study evaluate efficacy Losartan versus Atenolol progression aortic dilatation patient Marfan syndrome .</brief_summary>
	<brief_title>Atenolol Versus Losartan Prevention Progressive Dilation Aorta Marfan Syndrome</brief_title>
	<detailed_description>Marfan syndrome genetic disease connective tissue . Patients Marfan syndrome experience expansion aorta lead dissection rupture . This main cause mortality patient . The main objective study evaluate efficacy Losartan versus Atenolol progression aortic dilation patient Marfan syndrome . The measurement make echocardiography , assess diameter aorta different zone : valve annulus , sinuses Valsalva , sinotubular junction , ascend aorta , aortic arch , thoracic abdominal aorta . A total number 150 subject diagnose Marfan syndrome meet diagnostic criterion Ghent , sex , 75 per treatment group , age 5 60 , include study . The study conduct two Spanish hospital . The treatment maintain throughout study period .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Dilatation , Pathologic</mesh_term>
	<mesh_term>Marfan Syndrome</mesh_term>
	<mesh_term>Arachnodactyly</mesh_term>
	<mesh_term>Atenolol</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>1 . Subjects must conform diagnostic criterion Marfan syndrome accord Ghent Criteria . 2 . Outpatient subject . 3 . Male female , age 5 60 year . 4 . Women childbearing age require result negative Gonadotropin pregnancy test include study . 5 . Subjects must able take oral medication . 6 . After receive information study , subject must understand nature give write informed consent . 7 . For Subjects 18 year , informed consent must sign parent guardian . 8 . Subjects maximum diameter aorta , length , &lt; 45 mm 9 . Female subject childbearing potential must willing avoid pregnancy use adequate method contraception four week prior , three month last dose study medication . For purpose study , woman childbearing potential define : All female subject puberty unless postmenopausal least two year , surgically sterile . Adequate contraception define two barrier method , one barrier method spermicide , intrauterine device use oral female contraceptive ( hormonal method ) . 1 . Women pregnant , suspect pregnant breastfeeding . 2 . Ongoing participation another clinical trial receive investigational drug month prior inclusion study . 3 . Known suspected failure comply study protocol . 4 . Previous surgery : cardiac segment aorta . 5 . Functional class IIIIV . 6 . Maximum diameter aorta exceed 45 mm 7 . More moderate valvular involvement . 8 . History presence respiratory failure , liver ( ALT &gt; 3 x ULN ) , renal ( creatinine clearance &lt; 30 mL / min ) , gastrointestinal , hematological , endocrine , situation may affect assessment study treatment , accord investigator opinion . 9 . History aortic dissection . 10 . History presence neurological disease ( especially seizures , dementia ... ) . 11 . History presence alcohol abuse / toxic substance 12 . Uncontrolled depression . 13 . Any need another antihypertensive treatment ( betablockers , diuretic , calcium channel blocker , ACE inhibitor , ARBs , etc . ) 14 . Hypersensitivity , intolerance contraindication component study drug . 15 . Patients history drug abuse toxic dependence .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Aortic dilation</keyword>
	<keyword>Marfan syndrome</keyword>
	<keyword>Losartan</keyword>
	<keyword>Atenolol</keyword>
</DOC>